Age <60 | Age 60–69 | Age 70–79 | Age 80+ | All ages | |
---|---|---|---|---|---|
Total (n) | 251 | 403 | 366 | 82 | 1102 |
Alive at 3 years (n) | 154 | 198 | 117 | 7 | 476 |
Relative 3 year survival (%) | 62% | 52% | 38% | 13% | 47% |
Overall 3 year survival (%) and univariate p values | Multivariable | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
% | p value | % | p value | % | p value | % | p value | HR | p value | |
HR = hazard ratio for death; RT = radiotherapy. | ||||||||||
*Stage I or II. | ||||||||||
†Reference category. | ||||||||||
Age | ||||||||||
<60 | 61 | 0.84 | 0.1 | |||||||
60–69† | 49 | 1 | ||||||||
70–79 | 32 | 1.28 | 0.007 | |||||||
80+ | 8 | 1.31 | 0.07 | |||||||
Sex | ||||||||||
Female† | 69 | 51 | 43 | 18 | 1 | |||||
Male | 57 | 0.1 | 48 | 0.8 | 30 | 0.1 | 6 | 0.7 | 0.86 | 0.2 |
Histology | ||||||||||
Squamous cell† | 66 | 49 | 30 | – | 1 | |||||
Adenocarcinoma | 60 | 53 | 44 | – | 1.10 | 0.4 | ||||
Large cell undifferentiated | 37 | 0.1 | 38 | 0.5 | 24 | 0.03 | – | 1.08 | 0.4 | |
Tumour size | ||||||||||
T1† | 78 | 69 | 42 | – | 1 | |||||
T2 | 51 | <0.001 | 39 | <0.001 | 27 | 0.007 | – | 1.62 | <0.001 | |
Comorbidity | ||||||||||
0† | 53 | 53 | 38 | 10 | 1 | |||||
1 | 66 | 48 | 33 | 4 | 0.94 | 0.5 | ||||
2+ | 59 | 0.2 | 43 | 0.2 | 30 | 0.2 | – | 0.5 | 1.13 | 0.2 |
Treatment | ||||||||||
RT† | – | 21 | 10 | – | 1 | |||||
Surgery±RT | 63 | 57 | 47 | – | 0.49 | <0.001 | ||||
Other/none | – | – | <0.001 | 2 | <0.001 | – | 1.35 | 0.02 |